keyword
MENU ▼
Read by QxMD icon Read
search

Revlimid

keyword
https://www.readbyqxmd.com/read/29706958/one-year-follow-up-of-natural-killer-cell-activity-in-multiple-myeloma-patients-treated-with-adjuvant-lenalidomide-therapy
#1
Laurie Besson, Emily Charrier, Lionel Karlin, Omran Allatif, Antoine Marçais, Paul Rouzaire, Lucie Belmont, Michel Attal, Christine Lombard, Gilles Salles, Thierry Walzer, Sébastien Viel
Multiple myeloma (MM) is a proliferation of tumoral plasma B cells that is still incurable. Natural killer (NK) cells can recognize and kill MM cells in vitro and can limit MM growth in vivo . Previous reports have shown that NK cell function is impaired during MM progression and suggested that treatment with immunomodulatory drugs (IMIDs) such as lenalidomide (LEN) could enhance it. However, the effects of IMIDs on NK cells have been tested mostly in vitro or in preclinical models and supporting evidence of their effect in vivo in patients is lacking...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29445113/a-decade-of-progress-in-myelodysplastic-syndrome-with-chromosome-5q-deletion
#2
REVIEW
Alan List, Benjamin L Ebert, Pierre Fenaux
There are few instances in oncology where reciprocal clinical and laboratory translation studies have accelerated the understanding of disease biology and treatment more so than the decade following the Food and Drug Administration (FDA) approval of lenalidomide (RevlimidTM ; Celgene Corporation, Summit, NJ, USA) for the treatment of patients with myelodysplastic syndrome (MDS) and chromosome 5q deletion (del(5q)). Lenalidomide was approved by the FDA in December 2005 on the merits of a multicenter phase 2 study, which demonstrated sustained and prolonged transfusion independence in the majority of participants...
January 30, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29411269/single-dose-comparative-pharmacokinetics-of-two-formulations-of-lenalidomide-25-mg-in-healthy-subjects-a-randomized-crossover-study
#3
SeungHwan Lee, Jun Gi Hwang, Sang Yeob Park, Hye Jung Lim, Sa-Won Lee, Min-Hyo Seo, JaeWoo Kim, Jang Hee Hong
BACKGROUND: Lenalidomide is used for the treatment of multiple myeloma in combination with dexamethasone. The purpose of this study was to compare the pharmacokinetics (PKs) and assess the bioequivalence of two formulations of lenalidomide 25 mg: Lenalid® 25 mg tablet (test formulation) and Revlimid® 25 mg capsule (reference formulation). METHODS: A randomized, single-dose, two-treatment, two-period, two-sequence crossover study was conducted in 42 healthy subjects...
February 2018: Advances in Therapy
https://www.readbyqxmd.com/read/28860442/-effective-bird-therapy-after-the-addition-of-clarithromycin-for-lenalidomide-and-dexamethasone-resistant-multiple-myeloma-ineligible-for-stem-cell-transplantation
#4
REVIEW
Shogo Miura, Hiroyuki Kuroda, Michiko Yamada, Ken Sato, Saki Ameda, Hiroya Sakano, Takanori Shibata, Naoki Uemura, Tomoyuki Abe, Shigeyuki Fujii, Masahiro Maeda, Masayoshi Kobune, Junji Kato
BiRd combination therapy, which comprises clarithromycin(CAM: Biaxin®), lenalidomide(LEN: Revlimid®), and dexamethasone( DEX), is a highly effective treatment for newly diagnosed symptomatic multiple myeloma(MM). However, its efficacy against recurrent myeloma refractory to LEN and DEX combination therapy(Rd therapy)remains unclear. In this study, we retrospectively analyzed the data of 7 patients(4 men and 3 women, median age of 76 years)with MM, who had clarithromycin added to their Rd regimen. In all patients, the starting dose of clarithromycin was 400 mg daily and the median number of prior therapies was 3(range, 1-4)...
August 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28828689/lenalidomide-in-combination-with-bendamustine-and-prednisolone-in-relapsed-refractory-multiple-myeloma-results-of-a-phase-2-clinical-trial-osho-077
#5
MULTICENTER STUDY
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, Lars-Olof Mügge, Jens Uhlig, Simone Heyn, Brigitte Kragl, Martin Mohren, Franz Albert Hoffmann, Thoralf Lange, Thomas Schliwa, Thomas Zehrfeld, Cornelia Becker, Ute Kreibich, Cornelia Winkelmann, Thomas Edelmann, Marc Andrea, Marius Bill, Madlen Jentzsch, Sebastian Schwind, Dietger Niederwieser, Wolfram Pönisch
INTRODUCTION: While lenalidomide monotherapy is established for relapsed and/or refractory multiple myeloma (MM) treatment, combination therapies including lenalidomide are still under investigation in a number of phase 2/3 studies. In the current study, a treatment regime of lenalidomide (Revlimid® ), bendamustine and prednisolone (RBP) was tested in patients with relapsed/refractory MM. METHODS: In the previously completed phase 1 study RBP with a dose of 75 mg/m2 bendamustine days 1-2, prednisolone 100 mg days 1-4 and 25 mg lenalidomide days 1-21 was well tolerated...
December 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28791622/lenalidomide-a-review-in-newly-diagnosed-multiple-myeloma-as-maintenance-therapy-after-asct
#6
Yahiya Y Syed
Lenalidomide (Revlimid® ) is an immunomodulatory drug with multiple mechanisms of action against multiple myeloma. It is a thalidomide analogue, with improved potency and reduced toxicity compared with thalidomide. In the EU and USA, lenalidomide monotherapy is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem-cell transplantation (ASCT). In the pivotal, phase 3 IFM 2005-02 and CALGB 100104 trials, lenalidomide maintenance therapy after ASCT administered until disease progression significantly prolonged progression-free survival (PFS; primary endpoint) relative to placebo in patients with newly diagnosed multiple myeloma...
September 2017: Drugs
https://www.readbyqxmd.com/read/28655091/-outcomes-of-lenalidomide-based-treatment-for-57-patients-of-relapsed-or-refractory-multiple-myeloma
#7
S H Deng, Y Xu, W W Sui, G An, X H Mao, Z J Li, D H Zou, L G Qiu
Objective: To investigate the clinical efficacy and safety of lenalidomide (Revlimid, R) -based chemotherapy in the treatment of relapsed/refractory multiple myeloma (MM) patients. Methods: 57 consecutively relapsed/refractory MM patients were retrospectively analyzed from June 2013 to February 2016. All the patients received lenalidomide-based chemotherapy. Results: ① 60.4% patients had international staging system (ISS) stage Ⅲ, 37.9% patients had revised international staging system (R-ISS) stage Ⅲ, and 53...
June 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/28106903/continuous-treatment-with-lenalidomide-and-low-dose-dexamethasone-in-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma-in-asia-subanalysis-of-the-first-trial
#8
RANDOMIZED CONTROLLED TRIAL
Jin Lu, Jae H Lee, Shang-Yi Huang, Lugui Qiu, Je-Jung Lee, Ting Liu, Sung-Soo Yoon, Kihyun Kim, Zhi X Shen, Hyeon S Eom, Wen M Chen, Chang K Min, Hyo J Kim, Jeong O Lee, Jae Y Kwak, Wai Yiu, Guang Chen, Annette Ervin-Haynes, Cyrille Hulin, Thierry Facon
The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Given genetic differences between Asian and Western populations, this subanalysis of the FIRST trial examined the safety and efficacy of Rd (given continuously or for 18 cycles [Rd18]) and MPT (melphalan, prednisone, thalidomide) in 114 Asian patients from Mainland China, South Korea and Taiwan...
March 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/27983764/bendamustine-lenalidomide-and-dexamethasone-brd-has-high-activity-as-2-nd-line-therapy-for-relapsed-and-refractory-multiple-myeloma-a-phase-ii-trial
#9
MULTICENTER STUDY
Ulrich J M Mey, Wolfram Brugger, Heike Schwarb, Stefanie Pederiva, Andreas Schwarzer, Tobias Dechow, Paul Jehner, Jacqueline Rauh, Christian J Taverna, Mathias Schmid, Martin Schmidt-Hieber, Steffen Doerfel, Natalie Fischer, Axel Ruefer, Carsten Ziske, Wolfgang Knauf, Richard Cathomas, Roger von Moos, Felicitas Hitz, Rafael Sauter, Elke Hiendlmeyer, Nathan Cantoni, Mario Bargetzi, Christoph Driessen
The combination of lenalidomide (Revlimid®, R) and dexamethasone (d) is a standard regimen for patients with relapsed/refractory multiple myeloma (rrMM). With this regimen, only a small fraction of patients will achieve high quality responses [≥ very good partial response (VGPR)]. The combination of bendamustine (B), lenalidomide and dexamethasone (BRd) has shown high efficacy in patients with advanced rrMM. However, dose-limiting haematotoxicity restricted its use in extensively pre-treated patient populations...
March 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/27668061/revlimid-lenalidomide-now-fda-approved-as-first-line-therapy-for-patients-with-multiple-myeloma
#10
Lisa A Raedler
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27544800/double-hit-follicular-lymphoma-with-myc-and-bcl2-translocations-a-study-of-7-cases-with-a-review-of-literature
#11
REVIEW
Yuan Miao, Shimin Hu, Xinyan Lu, Shaoying Li, Wei Wang, L Jeffrey Medeiros, Pei Lin
Follicular lymphoma with MYC and BCL2 translocations, so-called double-hit follicular lymphoma (DH-FL), is rare. Here, we report the clinicopathological features of 7 cases of DH-FL. All neoplasms had a follicular pattern (1 partially diffuse). Five cases were predominantly low grade, 4 of which had focal (≤20%) grade 3A areas, and 2 cases were of grade 3. All cases were positive for pan-B-cell antigens, CD10, and BCL6; 6 cases were positive for BCL2. Ki-67 was less than or equal to 50% in 6 cases and 90% in 1 grade 3 case...
December 2016: Human Pathology
https://www.readbyqxmd.com/read/27441522/diarrhea-in-multiple-myeloma-a-review-of-the-literature
#12
REVIEW
Beth Faiman
BACKGROUND: One of the most common and inadequately managed symptoms that patients with multiple myeloma (MM) experience as a result of cancer treatment is diarrhea. Diarrhea in patients with MM often is severe enough to warrant dose reduction, delays, or discontinuation of chemotherapy. Short-term diarrhea can occur as a side effect of drugs, such as bortezomib (Velcade®) or panobinostat (Farydak®). Late-onset diarrhea from lenalidomide (Revlimid®) can occur 17-24 months after the start of therapy...
August 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/27162471/lenalidomide-revlimid-a-thalidomide-analogue-in-combination-with-dexamethasone-for-the-treatment-of-all-patients-with-multiple-myeloma
#13
Martin Paspe Cruz
No abstract text is available yet for this article.
May 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/26321720/-a-newly-diagnosed-case-of-multiple-myeloma-in-which-lenalidomide-was-continued-after-surgery-for-a-pancreatic-neuroendocrine-tumor-that-developed-during-lenalidomide-maintenance-therapy
#14
Hiroyuki Kuroda, Masahiro Yoshida, Makoto Usami, Saori Shimoyama, Hiroki Sakamoto, Michiko Yamada, Shigeyuki Fujii, Masahiro Maeda, Miri Fujita, Yusuke Kanari, Tsutomu Sato, Junji Kato
A 75-year-old woman was diagnosed with symptomatic IgG-l multiple myeloma (good-prognosis group) in December 2010. A stringent complete response (sCR) was achieved by using induction therapy with bortezomib (BOR, Velcade®)+ dexamethasone (DEX)(VD) and consolidation therapy with BOR+lenalidomide (LEN, Revlimid®)+DEX(VRD). Although maintenance therapy with Revlimid®+DEX(Rd) was initiated, a pancreatic neuroendocrine tumor was detected in April 2013. Therefore, LEN was discontinued and distal pancreatectomy was performed in September 2013...
August 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25925941/lenalidomide-a-review-of-its-continuous-use-in-patients-with-newly-diagnosed-multiple-myeloma-not-eligible-for-stem-cell-transplantation
#15
REVIEW
Paul L McCormack
Lenalidomide (Revlimid(®)) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible for stem-cell transplantation. In randomized, controlled clinical trials, continuous lenalidomide therapy, either in combination with dexamethasone (FIRST trial) or as maintenance monotherapy following induction with melphalan/prednisone/lenalidomide (MM-015 trial), significantly improved progression-free survival (PFS) compared with induction therapy alone (with non-lenalidomide- or lenalidomide-containing regimens) in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation...
May 2015: Drugs & Aging
https://www.readbyqxmd.com/read/25342294/severe-resistant-hypocalcemia-in-multiple-myeloma-after-zoledronic-acid-administration-a-case-report
#16
Adrian P Noriega Aldave, Shikha Jaiswal
INTRODUCTION: Hypercalcemia is one of the most common metabolic abnormalities encountered in any form of malignancy. Hypocalcemia, however, is a rare manifestation, especially in cancers with bone involvement. Here we present a case of hypocalcemia in a patient with multiple myeloma that was refractory to treatment. CASE PRESENTATION: A 73-year-old African American woman recently diagnosed with multiple myeloma, presented with a 2-day history of fever, vomiting and hypocalcemia...
October 23, 2014: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/25248908/-three-cases-of-lenalidomide-resistant-iga-myeloma-for-which-a-response-was-regained-after-the-addition-of-clarithromycin
#17
Hiroyuki Kuroda, Wataru Jomen, Masahiro Yoshida, Makoto Usami, Michiko Yamada, Tomoyuki Abe, Tamaki Sakurai, Shigeyuki Fujii, Masahiro Maeda, Teppei Matsuno, Masanori Sato, Yusuke Kanari, Junji Kato
BiRd combination therapy, which comprises clarithromycin (CAM: Biaxin®), lenalidomide (LEN: Revlimid®), and dexamethasone ( DEX), is a highly effective treatment for newly diagnosed symptomatic myeloma. However, its efficacy against recurrent myeloma refractory to combination therapy with LEN and DEX(Rd therapy) remains unclear. Here, we report on BiRd therapy administered to three patients with IgA myeloma exacerbated during Rd therapy and for whom transplantation was not indicated, by adding CAM to the Rd regimen...
September 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25188483/current-advances-in-non-proteasome-inhibitor-based-approaches-to-the-treatment-of-relapsed-refractory-multiple-myeloma
#18
REVIEW
Abhishek Singla, Shaji Kumar
In the past decade, immunomodulatory drugs have been approved by the US Food and Drug Administration for the treatment of multiple myeloma (MM)-and a number of emerging agents that target the cellular pathways or proteins involved in the pathophysiology of MM are currently in development. Lenalidomide (Revlimid) and pomalidomide induce apoptosis and sensitize MM cells while demonstrating superior efficacy and better tolerability than thalidomide (Thalomid). Several novel classes of drugs, including the histone deacetylase (HDAC) inhibitors, heat shock protein (HSP) inhibitors, and monoclonal antibodies have been shown to have activity in myeloma in early-stage clinical trials...
November 15, 2011: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/25188481/treatment-related-adverse-events-in-patients-with-relapsed-refractory-multiple-myeloma
#19
REVIEW
Ravi Vij
In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin. These are commonly used in the treatment of relapsed/refractory (R/R) multiple myeloma (MM), but there is no universally accepted standard treatment. Salvage therapy must be tailored according to an individual patient's clinical profile, with the risks and potential effects of treatment-related adverse events being major determinants of the choice of therapy...
November 15, 2011: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/25146584/phase-i-ii-trial-of-oral-cyclophosphamide-prednisone-and-lenalidomide-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
#20
Donna E Reece, Esther Masih-Khan, Eshetu G Atenafu, Victor H Jimenez-Zepeda, Peter Anglin, Christine Chen, Vishal Kukreti, Joseph R Mikhael, Suzanne Trudel
This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma. The maximal administered dose of CPR consisted of cyclophosphamide 300 mg/m(2) on day 1, 8, and 15, lenalidomide 25 mg on d 1-21 and prednisone 100 mg every other day in a 28-d cycle. Between November 2007 and June 2009, 32 patients were entered in cohorts of three at three dose levels...
January 2015: British Journal of Haematology
keyword
keyword
12312
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"